ArticleInvestigative ophthalmology & visual science2026
Annexin A1 as a Key Modulator of Inflammatory, Glial, and Angiogenic Signaling Pathways in Diabetic Retinopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Annexin A1 (AnxA1) regulates inflammation and neovascularization in ocular diseases, influencing growth factor signaling and cytoskeletal dynamics. Accordingly, this study aimed to investigate the role of the AnxA1 protein in diabetic retinopathy (DR) and to understand how its absence affects inflammation and vascular dysfunction in DR. Methods: DR model was induced 12 weeks after streptozotocin injection in wild-type (AnxA1+/+) and AnxA1 knockout (AnxA1-/-) mice. We evaluated the consequences of AnxA1 deficiency on retinal morphology, Müller cell activation, inflammation, and angiogenesis associated with DR. We also performed an in silico analysis in wild-type animals with DR induced for 6 weeks and in a dataset of patients with DR. Furthermore, a choroidal neovascularization model was used to evaluate the role of AnxA1 in angiogenesis signaling. Results: AnxA1 deficiency exacerbated selective systemic inflammatory alterations and promoted retinal neurodegeneration associated with DR. AnxA1-/- diabetic animals exhibited increased circulating IL-6, IL-17, chemokine (C-X-C motif) ligand 1, and monocyte chemoattractant protein-1 levels, retinal monocyte chemoattractant protein-1 and IL-4 upregulation, dysregulated MAPK/STAT3 signaling, and altered gliosis responses. In addition, AnxA1 deficiency was associated with a proangiogenic signaling profile characterized by increased retinal levels of EGF, VEGF-A, and endothelin-1 in DR, whereas the upregulation of VEGF-C was predominantly observed in the choroidal neovascularization model. Conclusions: Endogenous AnxA1 modulates inflammatory-glial and proangiogenic signaling pathways in the diabetic retina. Its deficiency is associated with selective inflammatory dysregulation and enhanced angiogenesis-related signaling during DR progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.